BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan - 2More parents refusing vitamin K shots for newborns, study finds
- 3Most loved Specially prepared Espresso Mix: Which Meal Do You Adore the Most?
- 43D Printers for Specialists
- 5Educated: How to Take full advantage of Your Gadgets
- Hoist Your Style: Famous Hairdos for Ladies
- Germany and trade unions kick off tough public-sector wage talks
- Understanding the Rudiments of Tree Administrations
- Newly discovered link between traumatic brain injury in children and epigenetic changes could help personalize treatment for recovering kids
- Go on A Careful spending plan: Modest Objections for Your List of must-dos
- Vote in favor of the juice that you love for its medical advantages!
- Manual for Financial plan Cordial PC
- 5 Chiefs That Changed Our Opinion on Film
- Sound and Delightful: 12 Nutritious Smoothie Recipes
